Melanoma Clinical Trials

Showing 241-260 of 1,477 trials

Axitinib + Ipilimumab in Advanced Melanoma

NCT04996823

The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.

Melanoma

H. Lee Moffitt Cancer Center and Research Institute25 participantsStarted Aug 2021

Tampa, Florida, United States

Active Not RecruitingNA

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

NCT02307630

The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections. Antibodies can be made by your own body or in a laboratory. The target of an antibody is called an antigen; antibodies fit their antigen like a lock fits a key.

MelanomaNeuroblastomaSarcoma

Memorial Sloan Kettering Cancer Center7 participantsStarted Nov 2014

New York, New York, United States

Active Not RecruitingPhase 2

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more

National Cancer Institute (NCI)5 participantsStarted Oct 2020

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +169 more locations

Axitinib + Ipilimumab in Advanced Melanoma

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Related Searches

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Tebentafusp-tebn With LDT in Metastatic UM

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma